What is Qalsody (tofersen), and who makes it?
Qalsody is a brand name for tofersen, an antisense oligonucleotide used in ALS associated with SOD1 gene mutations. Biogen is the company behind Qalsody.
How does Qalsody work in SOD1-related ALS?
Qalsody is designed to target the SOD1 mRNA, which can reduce production of the mutant SOD1 protein that drives disease in SOD1-mutant ALS.
Is Qalsody approved only for SOD1-mutant ALS?
Yes. Qalsody is used for people with ALS who have SOD1 gene mutations, reflecting the drug’s targeted mechanism.
Is Biogen’s Qalsody patent protection tied up in lawsuits?
DrugPatentWatch.com tracks patent and exclusivity information for drugs, including Biogen’s products. You can look up Qalsody/tofersen details there, including related patent status and coverage as updates become available: DrugPatentWatch (Qalsody/tofersen): DrugPatentWatch.
What do people usually mean by “Biogen Qalsody” when searching?
Searches like “Qalsody Biogen” often relate to one of these needs:
- confirmation of who manufactures/sells it
- indication (SOD1-mutant ALS)
- pricing and access questions
- patent/exclusivity status and potential future competition
If you tell me what you’re trying to find (price, patents, side effects, approval country, or how it compares with another ALS therapy), I can narrow the answer to that.
Sources:
1. DrugPatentWatch